Postpartum Low-Dose Esketamine Aids Moms With Prenatal Depression
By Elana Gotkine HealthDay Reporter
MONDAY, April 15, 2024 -- A single low dose of esketamine after childbirth reduces depressive episodes at 42 days postpartum among mothers with prenatal depression, according to a study published online April 10 in The BMJ.
Shuo Wang, M.D., from Peking University First Hospital in Beijing, and colleagues conducted a randomized, double-blind trial with two parallel arms involving 364 mothers aged 18 years and older from five tertiary care hospitals in China with at least mild prenatal depression. Participants were randomly assigned to receive 0.2 mg/kg esketamine or placebo infused intravenously over 40 minutes after childbirth (180 and 181 women, respectively).
The researchers found that a major depressive episode was observed in 6.7 and 25.4 percent of mothers in the esketamine and placebo groups, respectively, at 42 days postpartum (relative risk, 0.26). The esketamine group had lower scores on the Edinburgh Postnatal Depression Scale at seven days (median difference, −3) and 42 days (median difference, −3). The esketamine group also had lower Hamilton Depression Rating Scale scores at 42 days postpartum (median difference, −4). The esketamine group had a higher incidence of neuropsychiatric adverse events (45.1 versus 22.0 percent); however, the symptoms lasted less than one day and did not require drug treatment.
"Low-dose esketamine should be considered in mothers with symptoms of prenatal depression," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Electroconvulsive Therapy Safe, Effective for Range of Serious Mental Illnesses
FRIDAY, April 26, 2024 -- Electroconvulsive therapy (ECT) is a safe and effective treatment for serious mental illness, according to a study presented at the annual congress of...
Dialectical Behavior Therapy Reduces Suicidal Behavior in Adults With Autism
MONDAY, April 22, 2024 -- Dialectical behavior therapy (DBT) is safe and shows short-term efficacy in reducing suicidal ideation and suicide attempts in adults with suicidal...
Visual Impairment Linked to Increased Risk for Suicide
FRIDAY, April 19, 2024 -- Visual impairment is associated with an increased risk for suicide, according to a systematic review and meta-analysis published online April 18 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.